Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 408
- Registration Number
- NCT04428151
- Locations
- 🇺🇸
Rush University Medical Center ( Site 1560), Chicago, Illinois, United States
🇺🇸Cleveland Clinic Main ( Site 1598), Cleveland, Ohio, United States
🇺🇸Boston Medical Center ( Site 1605), Boston, Massachusetts, United States
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT04375384
- Locations
- 🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
QUantitative Assessment of Swallowing After Radiation (QUASAR)
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Loren Mell, MD
- Target Recruit Count
- 42
- Registration Number
- NCT04359199
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 44
- Registration Number
- NCT04349267
- Locations
- 🇺🇸
Local Institution - 0001, Germantown, Tennessee, United States
🇺🇸Local Institution - 0028, Sioux Falls, South Dakota, United States
🇨🇦Local Institution - 0013, Ottawa, Canada
CIML NK Cell in Head & Neck Cancer
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT04290546
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure
- Conditions
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 50
- Registration Number
- NCT04278092
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 80
- Registration Number
- NCT04262635
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Jiangsu Cancer Institute & Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04241731
- Locations
- 🇨🇳
Jiangsu Cancer Institute & Hospital, Nanjing, Jiangsu, China
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Baruch Brenner
- Target Recruit Count
- 31
- Registration Number
- NCT04229459
- Locations
- 🇮🇱
Rabin Medical Center, Petach Tikva, Israel
Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Hôpital Franco-Britannique-Fondation Cognacq-Jay
- Target Recruit Count
- 72
- Registration Number
- NCT04189055
- Locations
- 🇫🇷
Franco-British Hospital - GCS IHFB Cognacq-Jay, Levallois-Perret, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.